variabl remain across evolv healthcar continuum
challeng drug util environ compound uncertainti around
potenti initi washington view opportun across
healthcar technolog distribut univers particularli meaning
recent valuat contract across group focu company-
specif driver ancillari busi unit strateg posit effort
tradit pharmaceut suppli chain compani also continu
view less convent healthcar name attract anim health
fundament remain strong favor compani
leverag global data asset view robust backdrop new
strateg focu dental compani inspir glacial recov
demand environ also recogn opportun recent commerci
contract shift consolid clinic lab landscap summar
best idea across broad coverag univers head
meaning growth opportun particularli gain deeper
access rapidli grow medicar advantag busi well
integr medical-pharmacy-retail solut find state nt synergi
opportun year two valuat also compel
zoeti outperform leader anim health lever
strengthen fundament earn growth acceler
consist revenu growth improv cost structur capit
deploy includ recent invest dog nostic supplement
growth underappreci dynam
ia hold outperform book billion merger-to-
date relat solut contribut meaning
top-line growth ahead industri exit view
leverag unmatch data asset size scale captur
greater share boast rel diversifi custom base
outperform asp pressur persist
like beyond view strategi target broader
market logic evolut potenti unlock vastli greater
address market time moreov room sever player
highli under-penetrated clear align market
adjust target price across specif compani variou factor
includ lacklust drug util environ regulatori overhang
labcorp lh outperform view multipl avenu growth across
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
lh diversifi platform despit continu headwind core lcd
strong cf gener offer capit deploy flexibl particularli
relev given role lead consolid smaller lab oper
under-perform remain neg bias
lt structur headwind particularli given recent shift offlin
advertis share fell view room
downsid custom acquisit cost escal risk call
includ industri consolid among catalyst
recommend
variabl remain across evolv healthcar continuum challeng drug
util environ compound uncertainti around potenti initi
washington view opportun across healthcar technolog
distribut univers particularli meaning recent valuat contract across
group focu company-specif driver ancillari busi unit strateg
posit effort tradit pharmaceut suppli chain compani
also continu view less convent healthcar name attract anim
fundament remain strong favor compani
leverag global data asset view robust backdrop new strateg focu
dental compani inspir glacial recov demand environ also
recogn opportun recent commerci contract shift consolid clinic
laboratori landscap provid summari best idea across broad
coverag univers head
investor convers larg center respect strateg reposit tactic
 jvs/partnership relat ancillari busi servic broader vertic
integr regulatori scrutini well underli drug price util dynam
continu theme explor topic
specif relat drug distributor despit continu lacklust
util environ increment optimist head
stabil gener price environ well increment healthier brand price
inflat landscap previous expect least better visibl thereon potenti
sourc near term relief said continu favor distributor exposur
provid diversif drug utilization/pr also provid
meanwhil focu across pbm pharmaci strateg reposit
includ complet vertic transact jvs/partnership across healthcar
servic continuum focu also next potenti larger scale transact
transform effort may perceiv competit respons amazon
headlin past year compound drug price regulatori scrutini major
vertic merger cvs/aetna uniqu address all-import dynam around total
cost care
favor suppli chain name
rel view regulatori landscap somewhat benign given
congression gridlock lame-duck presid scenario albeit potenti
headlin risk associ recent scrutini well polici propos
relev govern organ particularli drug price
broader healthcar legisl key focu republican-l
congress conjunct republican presid trump drove cautious relat
potenti repeal replac drug price among healthcar debat
weigh consider suppli chain name howev look forward
downplay polit risk highlight midterm elect house/sen major
split like drive polit gridlock prevent success transform healthcar
reform moreov view democrat-l hous steadfastli avoid strike
transform deal presid trump ahead elect cycl presid
could util meaning legisl victori sell point view
polit gridlock favor industri constitu across univers offer
enhanc visibl least minim volatil like halt meaning
chang medium-term
legisl gridlock offer potenti stabil larger scale healthcar reform
recent rule district court judg reed oconnor fort worth texa
constitution afford act lack thereof remain headlin risk
accord legal expert neil seigel recent challeng
weakest yet extraordinarili unlik stand given lack clear injuri erron
focu congress intent vs congress aggress non-sever
postur though seigel view challeng overturn remain
statu quo time appeal process ensu decis less clear
potenti multipl hear ahead final resolut time-frame view
remind decemb us district court judg reed oconnor fort worth
texa rule aca individu mandat unconstitut mandat
penalti drop given aca constitution upheld congress
tax author inclin believ remain stand line
seigel view highlight relev aca-rel commentari industri constitu
light potenti headlin risk
charl martineau univers toronto figur relev aca-rel commentari pharmaceut suppli chain constitu
impact elimin tax benefit
medicar part subsidi retire benefit
net posit expect less
cover live move exchang may
lead margin compress
modest benefit medicaid
anticip modest benefit top line
ramp slower anticip like greater
one two point co-
net-net tailwind modest expect jun
driver volum albeit
difficult quanitfi
net benefit new demand script creat insur plan like
pressur reimburs throughout cycl seek reduc feder
spend alter medicaid reimburs formula multi-sourc
benefit come medicaid expans term exchang popul
still identifi mani increment insur coverag
aetna earn exposur medicaid like exposur
focu high-touch patient care experi high-risk popul make
dplo well-posit anticip growth manag live
particularli respect manag medicaid coverag
net posit fill prescript doughnut hole provid rx coverag
uninsur immedi impact longer term benefit
posit -- care reform enhanc long-term prospect
healthcar reform patient come system
patient out-of-pocket issu impact access investor day
hc stimulu packag well reform provid good fuel long-term posit
perform jan optimist provid increment volum jan
difficult quanitfi effect demand believ
posit effect associ peopl get access care
clearli inid segment patient
system hospit side harder teas shift
channel behavior consist said never abl
discern increas volum potenti mani at-risk patient
coverag come system er
improv volum due also improv economi abil
pars impact requir studi expand
coverag premium deduct higher off-set
medic devic tax attach
expect
difficult discern impact
expect materi differ volum
improv volum hard
pars contribut
expect medicaid growth rate increas
signficaitnli result
medicaid expenditur growth
state govern growth
growth hsd appear driven larg medicaid expans
project occur nearli level
inpati util growth
driven part usag
hc newli cover peopl
gener peopl begin see fuller use entir system differ
place still cost pressur payment rate
bad debt pre-aca uninsur
also see posit impact greater util
benefit greater util
materi
expect benefit didnt complet materi patient
pay out-of-pocket longer period year also off-set
expect bad debt declin greater insur coverag
larger scale healthcar reform remain unlik view amidst gridlock
continu expect presid trump polici manifest govern
organ includ propos depart human servic
hh center medicar medicaid servic serv potenti
overhang notabl trump administr rhetor seem eas somewhat
recent month relat pharmaceut suppli chain servic
constitu role drug price healthcar expenditur growth provid relief
relev name said highlight relev recent propos includ
part propos endors relev pbm tool includ formulari
manag chang tone larg critic past sever
month notabl propos util pos rebate/dir scheme signal
meaning shift previou rhetor suggest complet remov
rebat underscor pbm valu proposit
price medicar part implement would
undermin privat sector negoti tool provid new pathway
govern negoti industri constitu view privat sector
negoti better price competit innov rather
move certain drug part part could repres opportun
pbm seen success negoti drug part drive greater
overal market opportun howev drug distributor implic mix
evolv healthcar continuum drug price util gener price
remain larg lacklust past year drug price reimburs
come focu cours increasingli seen compani
inclin consid larger scale vertic integr diversif
strategi follow year fail mega merger highlight two
success complet transform vertic transact may pressur
healthcar servic constitu follow suit strateg reposit otherwis
order remain competit
amidst broader healthcar expenditur growth vs
constitu increasingli sought opportun better control total healthcar spend
also deliv earn growth unitedhealthcar forefront
solidifi presenc pbm landscap acquisit catamaran
combin optumrx offer bring pharmaci medic benefit
manag larger scale umbrella combin compani
notabl got slow start unh optumrx third largest pbm script
volum behind express script health mco also maintain
intern pbm strategi includ other recent launch
intern offer
constitu offer stand-alone pharmaci benefit servic includ health
express script join trend two major vertic transact
acquir aetna acquir esrx view deal natur
evolut healthcar servic landscap provid longer term growth opportun
also drive increas potenti effici healthcar cost manag
key investor focu head relat strateg posit
pharmaceut suppli chain constitu potenti larger scale potenti light
evolut healthcar continuum investor question whether
walgreen boot allianc would
integr drug distributor
stake current competit respons two
aforement transact held note alreadi achiev substanti
synergi partnership howev given recent partnership
focu shift view could potenti acquir health plan said
view multipl would need compress commit transform
outsid larger scale suppli chain constitu strateg reposit
smaller tuck-in acquisit increas focu ancillari servic offer
well partnership jv continu shi away larger scale
vertic integr activ reposit store sole drug dispensari
healthcare/oth servic hub numer partnership like
remain seemingli commit jv/partnership strategi vs outright acquisit
time prais capit effici approach potenti
limit near term hard-hit catalyst stock also diplomat pharmaci neutral
remain limbo amidst recent challeng bud pbm unit howev
acknowledg activ environ across specialti pharmaci offer support
meanwhil though drug distributor tradit seen larg homogen
vari approach capit deploy contribut greater differenti
busi model three major distributor earn
substanti portion consolid oper profit busi outsid
tradit us pharmaceut distribut acknowledg certain issu
hinder growth ancillari servic pharmedium cordi
challeng continu favor compani exposur potenti faster grow
profit ancillari busi end-market
view prescript util price dynam stabl
prior two year base recent metric iqvia remain cautious
optimist underli dynam moreov view current conservat relat
pricing/util may provid increment upsid current forecast come year
said continu monitor price commentari meaning chang
repres anoth year unfavor util dynam demonstr
sluggish prescript volum off-set seemingli stabil gener price
environ consist year date trend track well commentari
relev industri constitu despit anda level remain inflat level rel
prior year industri constitu note pharmaceut manufactur chosen
launch product certain market bid stabil price environ also
note industri constitu highlight manufactur withdrawn
product market similar reason factor togeth bode well
continu price stabil
weight
im trx top
drug
hand brand price inflat recent becom concern
given rhetor washington meaning lower price increas light
dynam view street bake significantli lower brand price
expect line experi said recent variou pharmaceut
giant announc intent follow normal price hike
go forward brand price inflat still like remain headwind estimate
msd vs hsd previou year view fulli bake potenti upsid
light recent industri commentari
term pharmaceut util medic adher increasingli becom
key focu particularli stakehold better understand enhanc pharmaceut
manag lower healthcar expenditur associ care higher cost
set emerg room moreov shift pos po rebat may
also creat tailwind cost drug decreas pharmaci counter
custom may previous inclin walk away high cost prescript
anem experi said profit implic suppli chain
industri constitu albeit still better outcom oner structur elimin
topic head underli demand trends/prescript util
brand gener price trend cvs/aet ci/esrx implic potenti
market share shift due conflict interest hh health care initi
strateg reposit effort evolv healthcar continuum includ capit
deploy tactic expans non-tradit offer
overal transform billion acquisit aetna creat uniqu medic
pharmaci benefit offer alongsid retail platform integr care solut
proxim consum view combin offer meaning growth
opportun includ access aetna grow custom base particularli
medicar advantag busi compel health hub vision well potenti
packag integr medical-pharmaci solut across current commerci
employ client aetna potenti associ offer
sell season moreov revis synergi target upward million
end year major bucket includ busi integr estimate synergi
gener administr expens medic cost save
figur synergi target bucket cs estim
gener administr
improv adher close gap care patient
optim exist program readmiss prevent
care manag
view combin offer meaning growth opportun aetna
grow oper incom compound-annual-growth-rate support scale lead
divers custom base rel balanc portfolio
particularli benefit gain deeper access rapidli grow medicar advantag
busi aetna grown enrol market growth rate larg support
improv rate trend member rate plan well
continu geograph expans importantli aetna recent re-affirmed expect grow
busi million member mid-teen rate forese futur
said also acknowledg potenti conflict interest cvss health
plan client repres cvss pbm busi excl part could skeptic
work alongsid competitor howev manag recent emphas
legaci cvss pdp plan compet health plan past
expect compli regular audit increas confid firewal
protect confidenti potenti mitig customer-competitor skeptic
also view cvss health hub vision compel compon stori albeit
longer term opportun leverag aetna medic benefit design better
drive custom pharmaci oppos costli site care
potenti acceler adopt health hub servic intend
replac role primari care physician see opportun expand
low-acu hc servic offer leverag part minuteclin footprint like
store pilot launch earli earli
importantli introduc new net cost price model caremark segment
guarante averag net spend per prescript discount rebat model
respons rapidli chang pbm landscap recent drug price scrutini
attempt boost transpar model account impact
inflat shift drug mix well incorpor total valu rebat
caremark pass
plan sponsor offer
transpar meaning sell point plan sponsor light prior opaqu
could potenti lead increment higher averag win rate also note
potenti risk associ accept account inflat mix shift
share declin vs decreas current trade
pro forma ebitda view signific upsid warrant
opportun aetna combin woefulli underappreci view target
rebat
charl martineau univers toronto price impli ev/ebitda multipl view better reflect
encourag company-specif initi lower target price
owen minor walgreen
diplomat pharmaci reflect less
convict near term earn prospect lacklust util environ
regulatory/drug price uncertainti well medic pbm woe
result lead somewhat difficult compar given
revenu account chang vs prior cro
provid vari disclosur despit earli confus relat revenu
recognit shift healthi year net book trend
consist outperform expect import indic assess cro
fundament sentiment larg posit outperform
gener market vs support also robust biotech
fund environ line channel check investor increasingli look
sign peak state cro landscap look ahead believ recent
result continu strength demand/outsourc trend posit cro
well focu also increasingli center abil address
ineffici across drug develop process leverag data asset
concern potenti consolid pharma custom base percol
week bristol-my squibb bid major biopharma player celgen relat
particular deal awar previou relationship inventiv
celgen date june side previous note partnership
iclr april june lh april prxl june iqvia
april importantli less clear instig across
pharma acknowledg pharma posit headlin
provid overhang group view effort bolster innov
 pipelin oppos ration
relat lead clinic laboratori serv anoth transit year
navig reimburs cut associ clinic lab fee
schedul clf protect access medicar act pama well
contract shift aetna pama pressur easili quantifi
view increment reimburs pressur larg price
share hand recent contract shift difficult quantifi
earli junctur given associ price volum compon well potenti
offset said view street like taken conserv approach
contract shift light limit visibl doctor-provid chang
topic head fund environ continu outsourc shift
custom consolid pipelin ration progress integr data
offer pama headwind and/or revis impact contract shift lab
ia outperform ia compel cro idea inher less
follow evolv cro industri sentiment clearli build cours
around merger im oct follow skeptic regard valu
proposit combin entiti tangibl data point billion new
busi win merger-to-d relat iqv gener solut well
smaller data asset acquisit lead prah/symphoni
help spur increas investor confid competit advantag stem
legaci imss unmatch global data asset particularli relat patient recruit
broadli expedit clinic trial process
head view variou dynam underappreci street name
continu momentum new busi win specif tie gener
solut rwe strength dd well newer driver oce
past rfp virtual trial concept win date moreov
recent unveil new cost save program vision earli
implement stage could repres profit upsid
longer term proprietari data offer support high singl digit revenu growth
accompani profit margin leverag drive double-digit ep growth capit
deploy remain central iqv long term strategi bolt-on acquisit ad
bp annual top-lin growth state interest build
clinic technolog technolog solut platform sinc merger quintil
im health repurchas approxim billion worth share heighten
level share repurchas similar repurchas would
impli upsid estim
current trade price-to-earnings estim approxim line cro
peer averag multipl share vs decreas
 target price impli price-to-earnings multipl
labcorp lh outperform continu view multipl avenu growth across lh
diversifi platform reduc overal exposur broader lab industri
dynam rel competitor lh recent disclosur caught investor off-guard
note well disappoint high-level guidanc modest ep growth led lh
share declin novemb vs view
core lcd headwind fulli bake junctur potenti conservat offer
path upsid importantli lower lab volum partli associ
doctor preemptiv shift provid ahead exclus expir
could provid visibl contract shift come year particularli given
report indic competitor activ pull forward provid chang
said acknowledg persist volum challeng beyond
expect serv risk factor outperform view
also highlight covanc unit cdd rev key growth driver potenti
sourc upsid current estim segment unteth broader clinic laboratori
trend lh continu experi healthi revenu growth estimate
support robust outsourc demand/rfp flow expect covanc leverag
bolster abil fsp/apac well proprietari data asset expedit patient
recruit addit chiltern associ launchpad cost save also
enhanc profit profil
anoth growth lever includ capit deploy particularli relev given role
lead consolid smaller laboratori oper post-pama world importantli
 activ core lcd segment limit note valuat
disconnect lh larg view pama headwind fulli bake howev
pama step view lh likewis increas activ
said expect balanc capit deploy strategi continu invest across
lh current trade ev/ebitda estim histor
averag competitor respect moreov
sotp analysi ascrib ev/ebitda multipl line quest
diagnost core lcd impli remark low multipl cro
discount clinical/preclin peer share fell vs
decreas new target price impli
ev/ebitda multipl acknowledg near term volum challeng indic
compani data credit suiss estim factset note factset pull
report releas
compani data credit suiss estim factset note factset pull
report releas
continu view recent result continu strength demand/outsourc
trend posit well lower target price charl
river laboratori better reflect growth prospect amidst margin
headwind continu syneo health lower visibl
relat commerci busi labcorp headwind
core lcd segment larg relat contract shift pama
underli dynam remain perplex follow lacklust experi
overal consum trend particularli us continu lag would
expect improv macroeconom environ meanwhil disrupt high tech
equip trend due prior manufacturer/distributor strategi realign also weigh
investor sentiment compound company-specif oper issu
manag turnov inevit transition/re-build year
dental name self-help initi also continu remain posit
bias dental market light favor longer term demograph notabl
less exposur us polici uncertainti plagu tradit healthcar name
moreov nearer term would expect equip return stabl growth
easi comp compani lap distribut channel inventori shift european
sale also support biannual id confer
consum growth remain larg lacklust throughout great
consist explan industri constitu similar experi
said encourag convers lead dental manufactur
distributor annual dental summit detail somewhat encourag us
fundament compar prior year meet us consum trend
mix recent quarter sell-out trend suggest strengthen underli demand
view low single-digit growth expect reason consum head
see note cs dental summit
high tech equip trend continu overshadow impact chang
xray distribut sirona technolog becam effect septemb
realign result inventori destocking/stock distributor cours
well moreov also emphas end-market
weak stem greater demand compet stand-alone digit impress
system recent note price pressur associ
mix shift demand dynam gener digit dentistri remain
support long term tailwind dental constitu given note
custom digit scan cad/cam technolog light trend
expect sequenti improv experienc throughout easi comp
anniversari distribut channel shift behind us
figur summari dental revenu growth trend
topic head underli consumables/equip demand trend high
tech equip adopt market share shift public privat distributor
ftc complaint/tri innov id new entrant clear align industri
consolidation/divestitur presenc amazon headlin risk view
manag shift resourc alloc low-growth market condit
like controversi pick algn multipl compress meaning
all-tim high januari larg predic persist asp
headwind cautious around competitor product launch view
valuat correct overdon remain well ahead competit term
innov view abil address case vs
straumann clearcorrect on-going technolog product enhanc continu
foster sourc differenti mandibular advanc moreov
acknowledg sever recent compet clear align launch larg target simpler
case mild moder malocclus hybrid treatment bracket wire clear
align highlight room sever player under-penetrated
specif continu see signific growth opportun vastli
under-penetrated market clear align repres
malocclus case annual broaden focu encompass
simpler lower tier market non-comprehens case strateg shift unlock
greater address market time suffer malocclus vs seek
treatment logic evolut consum awar around clear align solut
expand view inher compress case mix shift view
case volum growth acceler offset improv clinic
awar consum sentiment technolog enhanc expand geograph
teen market focu continu achiev sustain dd growth
current trade ep estim five-year averag
multipl dental compani peer averag multipl share
trade vs decreas new target price
impli price-to-earnings multipl remain broadli posit
stock lower price target better reflect less visibl competit dynam
charl martineau univers toronto comprehens primer state clear align market
compani data credit suiss estim factset note factset pull
report releas
across dental name lower target price patterson compani
continu tough util environ lack visibl near
term earn growth also moder target price
amidst tough demand environ long road cost save also
continu view anim health compel unconvent healthcar play
continu strength demand along inher advantag human healthcar
includ effici sustain portfolio limit reimburs concern
amid broader macroeconom environ mark stock market volatil
uncertainti highlight anim health sector histor shown
resili recessionari period follow flurri activ spin merger
divestitur expect industri constitu continu strive enhanc
divers portfolio term speci therapeut class geographi
topic head new companion anim product launch pipelin
updat development/matur elanco anim health neutral
stand-alone entiti relat remain divestitur potenti divestiture/spin-
pharmaceut giant-own anim health busi merck bayer
industri consolid health us livestock particularli dairi rise
competit veterinari pharmaci
top pick zoeti outperform leader anim health highli
lever strengthen fundament post consist earn growth
above-market revenu growth improv cost structur capit deploy
supplement growth still underappreci dynam view
meaning incorpor newli acquir abaxi diagnost portfolio deal
close august expect double-digit top-line growth potenti
updat progress key pipelin project tripl combin parasiticid
felin pain repres catalyst forecast revenu growth
fuel inclus abaxi estimate bp launch geography/product line
extens apoquel china revolut us plu continu traction key
blockbust product apoquel cytopoint simparica strong underli demand
trend supplement ebitda margin expans bp ep
grow base forecast
current trade ep estim histor averag
multipl share rose vs declin
target price impli price-to-earnings multipl
continu face multipl headwind beyond specif form
continu resist veterinari practition lack broader endors among
suppli chain constitu ramp new initi big-box retail
larg player petsmart chewi pharmaci petco/express script henri
schein/vet first choic on-line veterinari mail-ord pharmaci space
other potenti set make meaning inroad near futur light
intensifi competit recent disclos plan shift advertis spend
on-line back tv advertis expens strategi face challeng
past broadli view need increasingli reli promot activ
advertis drive custom acquisit cost higher weigh profit
current trade ep estim well five-year averag
multipl still fulli reflect alreadi intens competit environ
favor veterinari channel share languish view
continu experi pressur multipl angl lower price
target under-perform less convict
near term growth prospect intensifi competit headwind step custom
compani data credit suiss estim factset note factset pull
report releas
compani data credit suiss estim factset note factset pull
report releas
credit suiss estim us bureau econom analysi
bia remain broadli posit anim health sector compel altern
howev moder target price elanco neutral
better reflect competit dynam well ownership overhang
also lower target price acknowledg
fewer near term catalyst nt expens associ new initi
companion anim like wont materi near term
lower tp current trade ep estim
five-year averag multipl dental compani
peer averag multipl share trade vs
decreas new target price
impli price-to-earnings multipl remain broadli posit
stock lower price target better reflect less visibl competit
risk includ competit econom malais
price month
 close
valuat metric
number share
manufactur system clear align
therapi intra-or scanner cad/cam digit servic use
dentistri orthodont dental record storag
price jan rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
lower target price continu view recent result
continu strength demand/outsourc trend posit cro
well lower target price charl river laboratori
better reflect growth prospect amidst margin
headwind continu
risk includ demand shift biotech fund
valuat metric
number share
price month
 close
charl river laboratori intern inc full servic earli
model research develop new drug devic
price jan rate neutral target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario assum continu
robust industri trend expedit pronounc synergi
recent acquisit near term acceler larg pharma
biotech demand consist price increas identif
greater margin expans opportun continu market share
grey sky scenario assum oper
disrupt miscu recent acquisit weak
pressur increas insourc competit
 close
lower target price encourag compani specif
initi lower target price diplomat pharmaci
reflect less convict near term earn prospect lacklust
util environ regulatory/drug price uncertainti well
risk includ shift demand regulatori factor integr headwind
valuat metric
number share
price month
 close
diplomat pharmaci independ specialti pharmaci
dispens pharmaceut patient complex chronic
price jan rate neutral target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario predic acceler
integr recent acquir pbm accompani earlier
expect execut cost synergi cross-sel
acceler de-lever allow dplo resum acquisit
strategi earlier expect strategi mind potenti
diversifi suppli chain acquir could like
grey sky scenario predic unexpect
slowdown specialti pharmaceut industri
regulatory/reimburs shift integr miscu
 close
lower target price encourag compani specif
initi lower target price hm hold
reflect less convict near term earn prospect lacklust
util environ regulatory/drug price uncertainti
risk includ competit health polici uncertainti implement
price month
 close
valuat metric
number share
price jan rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
 close
lower target price encourag compani specif
initi lower target price
walgreen
diplomat pharmaci
reflect less convict near term earn prospect lacklust
util environ regulatory/drug price uncertainti well
medic pbm woe dplo respect
risk includ demand shift capit deploy miscu
valuat metric
number share
price month
 close
global pharmaceut sourc
price jan rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
lower target price encourag compani specif
initi lower target price
walgreen
diplomat pharmaci
reflect less convict near term earn prospect lacklust
util environ regulatory/drug price uncertainti well
medic pbm woe dplo respect
risk includ drug price acquisit miscu
valuat metric
number share
price month
 close
healthcar servic product compani
distribut brand gener pharmaceut well broad
varieti medic surgic product
price jan rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
 close
lower target price across dental name lower
target price dentspli sirona amidst tough demand
environ long road cost save also limit visibl
risk includ demand shift execut
valuat metric
number share
price month
 close
dentspli design develop manufactur market
price jan rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
 close
lower target price bia remain broadli posit anim
sector compel altern healthcar invest particularli
amidst potenti challeng macro headwind howev
moder target price elanco neutral
better reflect competit dynam well ownership
risk includ epidemiolog weather regulatori competit fx
valuat metric
number share
price month
